Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin

Diabetes, Obesity and Metabolism

Volumn 16, Issue 12, 2014, Pages 1257-1264

  Reusch, J ^a   Stewart, M W ^b   Perkins, C M ^c   Cirkel, D T ^d   Ye, J ^b   Perry, C R ^b   Reinhardt, R R ^b   Bode, B W ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Pharmaceutical Product Development   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e Atlanta Diabetes Association   (United States)

Author keywords

Albiglutide; Glucagon like peptide 1 agonist; Incretins; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; INCRETIN; METFORMIN; PIOGLITAZONE; RGLP-1 PROTEIN;

ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84919783449     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12382     Document Type: Article

References (21)

1. Seino Y, Nanjo K, Tajima N, Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 2010; 1: 212-218.
2. Garber AJ, Abrahamson MJ, Barzilay JI et al. American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement - executive summary. Endocr Pract 2013; 19: 536-557.
3. Zinman B, Hoogwerf BJ, Duran Garcia S et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007; 146: 477-485.
4. Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 2009; 32: 1224-1230.
5. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
6. Druker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
7. Prately RE, Nauck MA, Barnett AH et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 2: 289-297.
8. Leiter LA, Carr MC, Stewart M, Jones-Leone A, Yang F, Handelsman Y. HARMONY 8: Once weekly (QW) GLP1 agonist albiglutide (Albi) vs sitagliptin (sita) in type 2 diabetes (T2D) pts with renal impairment: week 26 results (abstract). American Diabetes Association 73rd Scientific Sessions, 2013. Chicago, IL: American Diabetes Association, 68-OR.
9. rd Scientific Sessions, 2013. Chicago, IL: American Diabetes Association, 54-LB.
10. rd Scientific Sessions, 2013. Chicago, IL: American Diabetes Association, 58-LB.
11. rd Scientific Sessions, 2013. Chicago, IL: American Diabetes Association, 55-LB.
12. rd Scientific Sessions, 2013. Chicago, IL: American Diabetes Association, 52-LB.
13. American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
14. Inzucchi SE, Bergenstal RM, Buse JB, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
15. Madsbad S, Kielgast U, Asmar M et al. An overview of once-weekly GLP-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011; 13: 394-407.
16. Rosenstock J, Stewart MW. Albiglutide. Glucagon-like peptide GLP-1 receptor agonist, treatment of type 2 diabetes. Drugs Fut 2010; 35: 701-712.
17. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M, Albiglutide Study Group. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009; 32: 1880-1886.
18. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev 2011; 27: 528-542.
19. Byetta US Package Insert. San Diego, CA, Amylin Pharmaceuticals, 2011. Available for URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021773s029s030lbl.pdf. Accessed 27 February 2014.
20. Victoza US Package Insert. Princeton, NJ, Novo Nordisk, 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022341s020lbl.pdf. Accessed 27 February 2014.
21. Standring S (ed). Gray's Anatomy: The Anatomical Basis of Clinical Practice. 39th edn. London: Churchill Livingstone, 2005.